Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.
PHILADELPHIA, PA & SAN FRANCISCO, CA & SHANGHAI, China — Dispatch Bio and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) said they have entered into a clinical collaboration to conduct ...
Autoimmune diseases arise when the immune system mistakenly targets and damages the body’s cells and tissues as though they ...
Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny ...
The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Asianet Newsable on MSN
CRVS stock surges pre-market after Corvus expands equity raise to $175 million
Corvus increased its public stock offering to $175 million from $150 million, making 7.9 million shares of its common stock ...
T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...
Michael Kalos, Ph.D., is the founder and managing director of Next Pillar Consulting, where he advises biopharmaceutical and venture organizations. He is also a Venture Partner with Alloy Therapeutics ...
Corvus Pharmaceuticals, Inc. jumps 165% on Phase 1 soquelitinib atopic dermatitis data; learn key efficacy, funding, and ...
Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results